argenx SE (ARGX)
$802.64-1.19%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $49.9B
- Beta
- -0.02
- P/E (TTM)
- 29.18
- Short % float
- 2.17%
- Days to cover
- 4.9
- SI change
- +3.0%
- 1W
- -13.74%
- 1M
- -18.97%
- vs SPY 1W
- -13.60%
- vs SPY 1M
- -21.48%
Industry peers
FMP comparable companies · ranked by market cap
- 068270.KSCelltrion, Inc.$42.2T$184100.00
- 196170.KQAlteogen Inc.$15.8T$226500.00
- AMGNBUYAmgen Inc.$222.8BRECOVERYQ 22$412.84-1.13%
- GMAB.COGenmab A/S$151.6B$2470.00
- 688331.SSRemeGen Co. Ltd. Class A$58.0B$104.75
- UCB.BRUCB S.A.$37.7B$197.90
- BIIBBUYBiogen Inc.$33.8BBULLQ 19$228.90-0.22%
- INCYSELLIncyte Corporation$22.0BBEARQ 13$108.62-2.46%
- IPN.PAIpsen S.A.$11.8B$142.60
- TGTXSELLTG Therapeutics, Inc.$8.3BBEARQ 11$54.34-1.68%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on ARGX?
- LOPJLB’s latest quantitative signal on argenx SE (ARGX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ARGX in?
- argenx SE (ARGX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does argenx SE (ARGX) do?
- argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a…